Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Q3 2022 Earnings Presentation
17 slides from Telix Pharmaceuticals's earnings presentation, Oct 20, 2022
Slide 1: Q3 2022 Quarterly Business Update
Q3 2022 Quarterly Business Update Telix Pharmaceuticals (ASX:TLX) 20 October 2022
Slide 2: Disclaimer
Disclaimer The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied,
Slide 3: Today’s presenters
Today’s presenters Kyahn Williamson Dr Christian Behrenbruch Darren Smith SVP INVESTOR GROUP CEO AND GROUP CHIEF R E L AT I O N S & MANAGING DIRECTOR FINANCIAL OFFICER C O R P O R AT E C O M M U N I C AT I O N 3
Slide 4: Q3 2022 Highlights
Q3 2022 Highlights
Slide 5: Growth Strategy
Growth Strategy Delivering long-term value to shareholders and patients Commercial Late-stage therapeutic Global supply chain Future pipeline: diagnostics portfolio pipeline and manufacturing research & innovation Revenue from first High clinical and Foundation for long-term Robust evaluation of fut
Slide 6: Q3 2022 Highlights
Q3 2022 Highlights Strong sales performance underpins evolution to financial sustainability U.S. Illuccix sales Net cash utilisation Major milestone Therapy programs up 178% (2.8x) on significantly ahead: ZIRCON continue to progress launch quarter reduced to $5.3 Phase III readout with new data mill
Slide 7: Q3 2022 Key Financial Metrics
Q3 2022 Key Financial Metrics Momentum continues into second commercial quarter Total Revenue U.S. Commercial Sales Receipts From Customers Cash Balance $55.3M $53.7M $44.5M $117.1M Up 168 percent from Up 178 percent from Up 724 percent from As of 30 September 2022 $20.6M in Q2 2022 $19.3M in Q2 202
Slide 8: Illuccix® Commercial Momentum
Illuccix® Commercial Momentum Strong sales growth • U.S. sales of Illuccix up 178% (2.8x) to $53.7 million U.S. Sales Q2 versus Q3 (AUD$M) (US$36.4 million) 60.0 53.7 • Reimbursement beginning to impact sales positively 50.0 • 179 pharmacies routinely dispensing Illuccix across 40.0 2.8x the U.S. an
Slide 9: Financial Commentary
Financial Commentary OTelix —— ae
Slide 10: Operating Cash Flow
Operating Cash Flow Transition to Q3 delivers significant improvement in net operating cash outflow • Q3 is the first quarter to demonstrate positive impact of customer receipts from commercial sales (cash v revenue recognition) • Customer receipts $44.5 million, up from $5.4 million in Q2 2022 • Q2
Slide 11: Operating Expenditure
Operating Expenditure Focused investment in priority programs, gross margin improvement Revenue (AUD$M) and Gross Margin Percentage • Gross margin improvement of 9% from Q2 to Q3 55.3 60.0 reflects more normalised commercial operating costs 50.0 62% • Q2 2022 operating expenditure contained one-off
Slide 12: Milestones Ahead
xe} © ® iS < ” i) = L rm) is = Teli
Slide 13: Core pipeline: oncology & rare diseases
Core pipeline: oncology & rare diseases 1. Prostate-specific membrane antigen. 4. Bone marrow conditioning/rare diseases. Note: Shaded sections indicate expected development stage in the next 12 months 2. Carbonic anhydrase IX. 5. Cluster of differentiation 66. *Registry study. 3. Large amino acid t
Slide 14: TLX250-CDx: ZIRCON Phase III Readout Imminent
TLX250-CDx: ZIRCON Phase III Readout Imminent Major commercial opportunity in an area of unmet medical need Renal cancer rates have doubled in the last 50 years • 400,000 cases worldwide in 20201 and the incidental detection ZIRCON PHASE III of small renal masses is increasing STUDY DESIGN • Current
Slide 15: TLX250-CDx: Potential for Indication Expansion
TLX250-CDx: Potential for Indication Expansion Imaging and therapy candidates feature strongly at EANM 2022 Preliminary data from two investigator-led studies presented Triple Negative Breast Cancer at European Association of Nuclear Medicine (EANM): • OPALESCENCE Phase II feasibility study of TLX25
Slide 16: Upcoming catalysts
Upcoming catalysts ✓ ProstACT SELECT data readout Regulatory filing ✓ Illuccix Q3 Telix AI™ commercial ZIRCON ProstACT Phase III EU Brussels South TARGET update Regulatory study manufacturing patient readout Update facility operational dosing MILESTONES 2H 2022 LOOKING AHEAD TO 2023 ✓ ProstACT Illuc
Slide 17: Q&A
Q&A €) Telix
Telix Pharmaceuticals — Q3 2022 Earnings Presentation on 6ix